Trials / Not Yet Recruiting
Not Yet RecruitingNCT07480694
Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With ADC
Real-world Study of Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With Antibody-drug Conjugates
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 400 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a real-world study. we collected patients with advanced HER2-negative breast cancer previously treated with antibody-drug conjugates, and received eribulin mesylate-based therapy post-ADC. We retrospectively collect the data on previous systemic treatment, and prospectively collect the treatment data of the therapeutic regimens based on eribulin mesylate.
Conditions
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2027-12-01
- Completion
- 2028-02-01
- First posted
- 2026-03-18
- Last updated
- 2026-03-18
Source: ClinicalTrials.gov record NCT07480694. Inclusion in this directory is not an endorsement.